Vecin Mechanism of Action

Pharmacotherapeutic group: Capillary-stabilizing agents. ATC code: CO5CX03.
Pharmacology: Pharmacodynamics: The target site of aescin is the vascular wall. In pathologically raised permeability, aescin inhibits exudation by reducing the extravasations of fluid into the tissue and accelerating the subsidence of edema. The mode of action is based on changes in the permeability of the affected capillary walls. In addition, aescin raises capillary resistance, inhibits inflammatory processes and improves microcirculation.
Pharmacokinetics: The metabolism of oral administered aescin was studied in rats and mice. After oral administration of tritium-marked aescin, the administered activity absorbed from the gastrointestinal tract averaged 12% to 16%. Excretion occurs by both bile and urine. The rate of metabolism is bigger following oral administration than with intravenous application. The organ distribution of aescin is insignificant in the excretion organs liver and kidneys, compared to the increased blood level.
Absorption: Aescin is rapidly absorbed after oral administration with an absorption half-life of approximately 1 hour; however, it undergoes a significant first-pass effect, resulting in only a 1.5% bioavailability.
Distribution: Total protein binding: 86% to 94%.
Metabolism: Aescin undergoes first-pass metabolism in liver.
Excretion: Aescin has a total plasma clearance of 21.8 milliliters/minute (ml/min).
Approximately 0.1% of an oral dose is excreted unchanged in the urine.
Terminal half-life of 10 hours after oral administration.